ADARx Pharmaceuticals

As of June 30, 2026, pro forma cash, cash equivalents and short-term investments were about 924 million dollars, before the underwriters’ option.

With full exercise and the AbbVie private placement, gross proceeds totaled about 602.5 million dollars, and management guides cash runway into 2030. Debt is not highlighted, and TTM operating cash outflow in 1H26 was about 49.9 million dollars, implying multi‑year cushion.

The AbbVie collaboration added a 335 million dollar upfront and large contingent milestones, albeit recognized over time and not guaranteed.